Moreover, a randomized placebo-controlled double-blind phase II clinical trial including prostate cancer patients received genistein before radical prostatectomy indictaed that the level of the prostate cancer biomarker prostate-specific antigen (PSA) in blood was reduced compared to the control [633]. Here, PROS1 is linked to prostate carcinoma.